The Riga Institute, a Belgian laboratory, hopes to launch a clinical trial of the mosque's anti-retroviral vaccine, which scientists at the University of Louvain said they had developed and looked "promising."

The vaccine that the developers gave the name "RigaFax" after the laboratory to host the experiments is based on an old vaccine that was used against yellow fever.

Last Thursday, the Riga Institute team announced that this is the first test that "has proven successful in laboratory animals."

"If things go according to plan, we want to start the first human clinical trials before the end of the year," said Kay Dalmire, one of the researchers who worked on the vaccine.

Belgian researchers first tested the Corona virus vaccine in hamsters, through their airways, to test for pulmonary infections similar to those occurring in normal life during the Coron epidemic.

During the experiments, the team observed that hamsters vaccinated with the yellow fever vaccine did not give any trace of the newly invaded Corona virus.

The researchers also noted that a single dose of the vaccine was sufficient and that many animals were already vaccinated only ten days after vaccination.

"We started working on eight prototypes shortly after January 12, when Chinese researchers shared the genetic code of the virus over the Internet," said researcher Johannets.

Then we continued, "We are happy with the results, although there is still a long way to go."

Johann Knights is Professor of Virology at the University of Louvain (Belgium) and Head of Operations at the Rega Laboratory.

Dozens of drugs are being tested, and about 100 vaccines are working on the other hand.

Whether it comes to finding or preventing Covid-19 treatment, experiments are progressing at a fast pace, although the world is still awaiting discovery that will turn the disease around.

The World Health Organization (WHO) classifies about 100 ongoing projects in eight different categories, corresponding to proven or experimental vaccine types.

They are classic vaccines that rely on a "live attenuated" or "inactive" virus, and are called "subunit" vaccines that contain proteins (provide an antigen to which the immune system responds, without viral particles).

There are also vaccine projects using a "viral vector" that adopt advanced virus manufacturing techniques whose sole purpose is to obtain an immune response in humans.

Follow our latest local and sports news and the latest political and economic developments via Google news